Elinogrel potassium: Receptor antagonist antiplatelet therapy

P. A. Gurbel, D. Kereiakes, U. S. Tantry

Research output: Contribution to journalArticle

Abstract

(Chemical Equation Presented) The pharmacological management of cardiovascular disease patients with antiplatelet therapy has undergone dramatic changes in recent years with the development of new and more potent P2Y 12 receptor antagonists. These agents have been developed to address the limitations of the most widely used P2Y12 receptor antagonist, clopidogrel. Among the limitations of clopidogrel addressed are response variability and resistance. The latter has been linked to ischemic event occurrence and stent thrombosis in patients treated with percutaneous intervention (PCI). The irreversible effect of clopidogrel is problematic in patients needing urgent surgery. Treatment with the recently approved third-generation thienopyridine prasugrel was associated with less ischemic event occurrence and stent thrombosis compared to clopidogrel therapy in patients with acute coronary artery syndrome (ACS) undergoing PCI. However, greater bleeding, including life-threatening and fatal bleeding, was observed in the prasugrel-treated patients. Ticagrelor is a member of a new class of P2Y12 inhibitors, the cyclopentyl-triazolo-pyrimidines (CPTP), the first direct-acting, reversiblybinding, noncompetitive P2Y12 receptor antagonist. Ticagrelor therapy resulted in less ischemic event occurrence than clopidogrel in ACS patients. An important potential advantage of ticagrelor is lower mortality and less coronary artery bypass graft-related bleeding than clopidogrel. However, ticagrelor therapy was associated with dyspnea in both phase II and III clinical trials. Cangrelor, an adenosine triphosphate (ATP) analogue, is a parenteral, direct, competitive and reversible P2Y12 inhibitor associated with rapid onset and offset of platelet inhibition (within minutes). However, in phase III trials cangrelor was not superior to placebo in reducing ischemic events in patients undergoing PCI who were treated with clopidogrel alone. Elinogrel (PRT-060128) is a novel, direct-acting, competitive and reversible P2Y12 receptor antagonist. Elinogrel is a first-in-class sulfonylurea that may be administered intravenously or orally. The latter route of administration may facilitate the transition from immediate to long-term therapy. Results from the INNOVATE-PCI (phase II) trial regarding the safety and antiplatelet efficacy of elinogrel compared to clopidogrel will be published soon.

Original languageEnglish (US)
Pages (from-to)885-892
Number of pages8
JournalDrugs of the Future
Volume35
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

clopidogrel
Potassium
Purinergic P2Y Receptor Antagonists
Therapeutics
Acute Coronary Syndrome
Hemorrhage
Stents
Coronary Vessels
Thrombosis
Pyrimidines
Phase III Clinical Trials
Phase II Clinical Trials
elinogrel
Coronary Artery Bypass
Dyspnea

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Elinogrel potassium : Receptor antagonist antiplatelet therapy. / Gurbel, P. A.; Kereiakes, D.; Tantry, U. S.

In: Drugs of the Future, Vol. 35, No. 11, 11.2010, p. 885-892.

Research output: Contribution to journalArticle

Gurbel, P. A. ; Kereiakes, D. ; Tantry, U. S. / Elinogrel potassium : Receptor antagonist antiplatelet therapy. In: Drugs of the Future. 2010 ; Vol. 35, No. 11. pp. 885-892.
@article{1fdfcbc820d9435eb189f8ffee40f9fe,
title = "Elinogrel potassium: Receptor antagonist antiplatelet therapy",
abstract = "(Chemical Equation Presented) The pharmacological management of cardiovascular disease patients with antiplatelet therapy has undergone dramatic changes in recent years with the development of new and more potent P2Y 12 receptor antagonists. These agents have been developed to address the limitations of the most widely used P2Y12 receptor antagonist, clopidogrel. Among the limitations of clopidogrel addressed are response variability and resistance. The latter has been linked to ischemic event occurrence and stent thrombosis in patients treated with percutaneous intervention (PCI). The irreversible effect of clopidogrel is problematic in patients needing urgent surgery. Treatment with the recently approved third-generation thienopyridine prasugrel was associated with less ischemic event occurrence and stent thrombosis compared to clopidogrel therapy in patients with acute coronary artery syndrome (ACS) undergoing PCI. However, greater bleeding, including life-threatening and fatal bleeding, was observed in the prasugrel-treated patients. Ticagrelor is a member of a new class of P2Y12 inhibitors, the cyclopentyl-triazolo-pyrimidines (CPTP), the first direct-acting, reversiblybinding, noncompetitive P2Y12 receptor antagonist. Ticagrelor therapy resulted in less ischemic event occurrence than clopidogrel in ACS patients. An important potential advantage of ticagrelor is lower mortality and less coronary artery bypass graft-related bleeding than clopidogrel. However, ticagrelor therapy was associated with dyspnea in both phase II and III clinical trials. Cangrelor, an adenosine triphosphate (ATP) analogue, is a parenteral, direct, competitive and reversible P2Y12 inhibitor associated with rapid onset and offset of platelet inhibition (within minutes). However, in phase III trials cangrelor was not superior to placebo in reducing ischemic events in patients undergoing PCI who were treated with clopidogrel alone. Elinogrel (PRT-060128) is a novel, direct-acting, competitive and reversible P2Y12 receptor antagonist. Elinogrel is a first-in-class sulfonylurea that may be administered intravenously or orally. The latter route of administration may facilitate the transition from immediate to long-term therapy. Results from the INNOVATE-PCI (phase II) trial regarding the safety and antiplatelet efficacy of elinogrel compared to clopidogrel will be published soon.",
author = "Gurbel, {P. A.} and D. Kereiakes and Tantry, {U. S.}",
year = "2010",
month = "11",
doi = "10.1358/dof.2010.35.11.1529823",
language = "English (US)",
volume = "35",
pages = "885--892",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "11",

}

TY - JOUR

T1 - Elinogrel potassium

T2 - Receptor antagonist antiplatelet therapy

AU - Gurbel, P. A.

AU - Kereiakes, D.

AU - Tantry, U. S.

PY - 2010/11

Y1 - 2010/11

N2 - (Chemical Equation Presented) The pharmacological management of cardiovascular disease patients with antiplatelet therapy has undergone dramatic changes in recent years with the development of new and more potent P2Y 12 receptor antagonists. These agents have been developed to address the limitations of the most widely used P2Y12 receptor antagonist, clopidogrel. Among the limitations of clopidogrel addressed are response variability and resistance. The latter has been linked to ischemic event occurrence and stent thrombosis in patients treated with percutaneous intervention (PCI). The irreversible effect of clopidogrel is problematic in patients needing urgent surgery. Treatment with the recently approved third-generation thienopyridine prasugrel was associated with less ischemic event occurrence and stent thrombosis compared to clopidogrel therapy in patients with acute coronary artery syndrome (ACS) undergoing PCI. However, greater bleeding, including life-threatening and fatal bleeding, was observed in the prasugrel-treated patients. Ticagrelor is a member of a new class of P2Y12 inhibitors, the cyclopentyl-triazolo-pyrimidines (CPTP), the first direct-acting, reversiblybinding, noncompetitive P2Y12 receptor antagonist. Ticagrelor therapy resulted in less ischemic event occurrence than clopidogrel in ACS patients. An important potential advantage of ticagrelor is lower mortality and less coronary artery bypass graft-related bleeding than clopidogrel. However, ticagrelor therapy was associated with dyspnea in both phase II and III clinical trials. Cangrelor, an adenosine triphosphate (ATP) analogue, is a parenteral, direct, competitive and reversible P2Y12 inhibitor associated with rapid onset and offset of platelet inhibition (within minutes). However, in phase III trials cangrelor was not superior to placebo in reducing ischemic events in patients undergoing PCI who were treated with clopidogrel alone. Elinogrel (PRT-060128) is a novel, direct-acting, competitive and reversible P2Y12 receptor antagonist. Elinogrel is a first-in-class sulfonylurea that may be administered intravenously or orally. The latter route of administration may facilitate the transition from immediate to long-term therapy. Results from the INNOVATE-PCI (phase II) trial regarding the safety and antiplatelet efficacy of elinogrel compared to clopidogrel will be published soon.

AB - (Chemical Equation Presented) The pharmacological management of cardiovascular disease patients with antiplatelet therapy has undergone dramatic changes in recent years with the development of new and more potent P2Y 12 receptor antagonists. These agents have been developed to address the limitations of the most widely used P2Y12 receptor antagonist, clopidogrel. Among the limitations of clopidogrel addressed are response variability and resistance. The latter has been linked to ischemic event occurrence and stent thrombosis in patients treated with percutaneous intervention (PCI). The irreversible effect of clopidogrel is problematic in patients needing urgent surgery. Treatment with the recently approved third-generation thienopyridine prasugrel was associated with less ischemic event occurrence and stent thrombosis compared to clopidogrel therapy in patients with acute coronary artery syndrome (ACS) undergoing PCI. However, greater bleeding, including life-threatening and fatal bleeding, was observed in the prasugrel-treated patients. Ticagrelor is a member of a new class of P2Y12 inhibitors, the cyclopentyl-triazolo-pyrimidines (CPTP), the first direct-acting, reversiblybinding, noncompetitive P2Y12 receptor antagonist. Ticagrelor therapy resulted in less ischemic event occurrence than clopidogrel in ACS patients. An important potential advantage of ticagrelor is lower mortality and less coronary artery bypass graft-related bleeding than clopidogrel. However, ticagrelor therapy was associated with dyspnea in both phase II and III clinical trials. Cangrelor, an adenosine triphosphate (ATP) analogue, is a parenteral, direct, competitive and reversible P2Y12 inhibitor associated with rapid onset and offset of platelet inhibition (within minutes). However, in phase III trials cangrelor was not superior to placebo in reducing ischemic events in patients undergoing PCI who were treated with clopidogrel alone. Elinogrel (PRT-060128) is a novel, direct-acting, competitive and reversible P2Y12 receptor antagonist. Elinogrel is a first-in-class sulfonylurea that may be administered intravenously or orally. The latter route of administration may facilitate the transition from immediate to long-term therapy. Results from the INNOVATE-PCI (phase II) trial regarding the safety and antiplatelet efficacy of elinogrel compared to clopidogrel will be published soon.

UR - http://www.scopus.com/inward/record.url?scp=79956284748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956284748&partnerID=8YFLogxK

U2 - 10.1358/dof.2010.35.11.1529823

DO - 10.1358/dof.2010.35.11.1529823

M3 - Article

AN - SCOPUS:79956284748

VL - 35

SP - 885

EP - 892

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 11

ER -